Last reviewed · How we verify

NCT04734223

Neuroimaging Findings in Patients With COVID-19

Completed Last updated 4 February 2021
What this trial tests

trial testing Neuroimaging Findings in Patients With COVID-19 in Neuroimaging in 436 participants. Completed in 31 December 2020.

Timeline
1 April 2020
Primary endpoint
31 December 2020
31 December 2020

Quick facts

Lead sponsorSaglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment436
Start date1 April 2020
Primary completion31 December 2020
Estimated completion31 December 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

Who can join

18 and older, any sex, with Neuroimaging or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to discuss the neuroimaging findings and indications, epidemiological data, laboratory values, and the relationship of these variables with mortality in patients with COVID-19.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Neuroimaging

Currently open trials in the same condition.

Other Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04734223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing